Main Research Findings

1) PEA-P was found to have reinforcing and rewarding effects, as well as psychoactive properties that induced positive effects on psychomotor behavior.

2) PEA-P and its derivatives were shown to have selective inhibitory effects on dopamine transportation indicating its potential to be used to treat neuropsychiatric disorders.

Selected Data
1) The study performed by the research team of Ryu et al investigated the psychomotor, rewarding, reinforcing, and affective effects of β-phenylethylamine (β-PEA) while examining the contribution of dopamine D1 receptor signaling to these behavioral responses. Male C57BL/6 mice were used for the open-field, conditioned place preference (CPP), dopamine enzyme-linked immunosorbent assay (ELISA), and Western blot experiments, whereas male Sprague-Dawley rats were used for ultrasonic vocalization (USV) and intravenous self-administration studies. Animals were housed under controlled temperature, humidity, and 12-hour light/dark cycle conditions with free access to food and water, except during food training for the self-administration experiments, during which rats underwent controlled food restriction to facilitate operant responding. β-PEA and the selective dopamine D1 receptor antagonist SCH23390 were administered intraperitoneally or intravenously depending on the experimental protocol [1].
To evaluate the acute psychomotor effects of β-PEA, mice were first acclimated and habituated to the testing environment before receiving intraperitoneal injections of saline or β-PEA at doses of 3, 10, 30, or 50 mg/kg. Immediately following administration, animals were placed in an automated open-field chamber for 30 minutes. Behavioral software quantified total locomotor activity while trained observers measured stereotypic behaviors including circling and head-twitching responses. Temporal analyses were also performed by dividing the recording period into five-minute intervals, allowing the investigators to determine both the magnitude and duration of behavioral changes following β-PEA administration. To determine whether dopamine D1 receptor activation mediated these effects, an additional cohort of mice received SCH23390 before β-PEA administration, after which the same open-field behavioral assessments were conducted.
The rewarding properties of β-PEA were assessed using a conditioned place preference paradigm. Mice first completed a pre-conditioning session to determine baseline chamber preference. During the conditioning phase, animals received alternating injections of saline or β-PEA before being confined to either the drug-paired or saline-paired compartment over several days. A post-conditioning preference test was then conducted without drug administration, during which mice were allowed unrestricted access to both compartments. The primary outcome measures included time spent in the drug-paired chamber and the conditioned place preference score, calculated by comparing post-conditioning preference with baseline values. This paradigm allowed the researchers to determine whether repeated β-PEA exposure produced rewarding contextual associations indicative of abuse liability [1].
Positive affective responses to β-PEA were examined using ultrasonic vocalization recordings in rats. Following acclimation and habituation, baseline 50-kHz ultrasonic vocalizations were recorded before administration of either saline or 50 mg/kg β-PEA. Vocalizations were then continuously monitored for an additional 30 minutes using specialized ultrasonic microphones and analysis software. Because 50-kHz calls are widely recognized as indicators of positive emotional states in rodents, both the total number of vocalizations and their temporal distribution across five-minute intervals were analyzed to determine whether β-PEA induced positive affective behavior.
To evaluate reinforcing effects, rats underwent food training followed by surgical implantation of chronic jugular vein catheters for intravenous self-administration. After recovery, animals self-administered saline or β-PEA at doses of 0.1, 0.3, or 1.0 mg/kg per infusion during daily two-hour sessions under fixed-ratio schedules of reinforcement, progressing from FR1 to FR3 across eleven consecutive days. Responses on the active lever delivered an intravenous drug infusion followed by a timeout period, whereas inactive lever presses had no programmed consequence. After completion of fixed-ratio training, rats underwent a six-hour progressive-ratio session in which the response requirement increased after each infusion to determine the reinforcing strength of β-PEA by measuring total infusions, active and inactive lever responses, and breakpoint. Additional self-administration experiments incorporated SCH23390 pretreatment to determine whether dopamine D1 receptor blockade altered β-PEA-taking behavior [1].
To investigate the neurobiological mechanisms underlying these behavioral effects, separate groups of mice received acute saline or β-PEA before rapid dissection of the dorsal striatum. Dopamine concentrations were quantified using enzyme-linked immunosorbent assays, while Western immunoblotting measured expression of tyrosine hydroxylase (TH), dopamine transporter (DAT), phosphorylated DAT (p-DAT), and vesicular monoamine transporter-2 (VMAT-2). Protein extracts were separated by gel electrophoresis, transferred to PVDF membranes, incubated with specific primary and secondary antibodies, and quantified by densitometric analysis. Together, these complementary behavioral, biochemical, and pharmacological approaches enabled the investigators to comprehensively evaluate both the behavioral actions of β-PEA and the dopaminergic mechanisms responsible for its psychoactive and reinforcing properties [1].
2) The study by the research team of Kundu et al was designed to identify structural characteristics of 29 β-PEA derivatives that influence dopamine transporter (DAT) inhibition and to determine how these compounds interact with the human dopamine transporter at the molecular level. In addition to evaluating dopamine reuptake inhibition, the investigators performed molecular docking simulations to predict ligand-binding interactions and conducted functional experiments to determine how selected β-PEA derivatives affected dopamine D2 receptor (D2R) signaling. Together, these complementary biochemical, computational, and cellular approaches allowed the researchers to establish structure–activity relationships (SAR) and investigate the functional consequences of DAT inhibition [2].
The experimental studies utilized human embryonic kidney (HEK-293) cells that were either stably or transiently transfected with human dopamine transporter (hDAT) or dopamine D2 receptor constructs. Cells were maintained under standard culture conditions in minimal essential medium supplemented with fetal bovine serum, penicillin, and streptomycin. The test compounds consisted of 29 structurally distinct β-PEA derivatives. GBR12909, a well-characterized dopamine reuptake inhibitor, served as the reference compound during dopamine uptake experiments, while radiolabeled dopamine ([³H]-dopamine) and radiolabeled sulpiride ([³H]-sulpiride) were used to quantify dopamine transport and D2 receptor surface expression, respectively.
To measure dopamine transporter inhibition, investigators employed a dopamine reuptake assay using HEK-293 cells expressing human DAT. Cells grown in 24-well plates were first washed with uptake buffer containing physiological concentrations of sodium, potassium, calcium, magnesium, glucose, and antioxidants. The cells were then incubated with individual β-PEA derivatives for approximately 20 minutes at 37°C before the addition of radiolabeled dopamine. Uptake was allowed to proceed for five minutes, after which the reaction was terminated by washing the cells with ice-cold buffer. Cells were subsequently lysed overnight using sodium dodecyl sulfate, and the accumulated radioactivity was quantified with a liquid scintillation counter. Compounds that inhibited dopamine uptake by at least 20–30% during the initial screening were selected for detailed concentration-response testing. Dose-response curves were generated for these compounds, and half-maximal inhibitory concentration (IC₅₀) values were calculated using GraphPad Prism software to compare their inhibitory potency [2].
To better understand the molecular basis of dopamine transporter inhibition, the researchers performed computational docking simulations using generated structural models of the human dopamine transporter. The three-dimensional transporter structure underwent energy minimization before docking analyses were conducted. Two compounds demonstrating particularly strong dopamine reuptake inhibition, compounds 9 and 28, were selected for detailed modeling. Because both molecules possess chiral centers, all possible stereoisomers were generated and evaluated individually. Docking simulations were carried out using four different scoring algorithms to improve confidence in predicted ligand orientations and binding affinities. The docking search space was centered around the known dopamine-binding pocket, and predicted ligand interactions with amino acid residues within the transporter were visualized using molecular graphics software. This computational approach enabled comparison of stereochemical preferences, hydrogen bonding interactions, hydrophobic contacts, and predicted binding stability among the various isomers.
To determine whether inhibition of dopamine reuptake influenced dopamine receptor function, the investigators conducted a dopamine D2 receptor endocytosis assay. HEK-293 cells were transiently transfected with dopamine D2 receptors together with either a mock vector or human DAT. Following transfection and cell plating, cultures were stimulated with dopamine to induce receptor internalization. Surface D2 receptor expression was subsequently quantified using radiolabeled sulpiride, a hydrophilic ligand that selectively binds receptors remaining on the plasma membrane. Some experimental groups were pretreated with selected β-PEA derivatives prior to dopamine exposure to determine whether DAT inhibition altered receptor trafficking. The amount of surface receptor remaining after agonist stimulation served as an indirect measure of receptor endocytosis and allowed the investigators to evaluate whether dopamine transporter activity modulated dopamine receptor signaling [2].
The collected data were expressed as mean ± standard deviation, and statistical analyses were performed using one-way analysis of variance followed by Tukey’s post hoc multiple comparison test. Differences were considered statistically significant when the probability value was less than 0.05. By integrating radiolabeled uptake assays, molecular docking simulations, structure–activity relationship analyses, and functional receptor trafficking experiments, the investigators established a comprehensive framework for evaluating how structural modifications of β-phenethylamine derivatives influence dopamine transporter inhibition and downstream dopaminergic signaling [2].

Discussion
1) The results of the study by Ryu et al demonstrated that acute administration of β-PEA produced significant psychomotor, rewarding, reinforcing, and positive affective effects in rodents, with these behavioral changes closely associated with enhanced dopaminergic neurotransmission and activation of dopamine D1 receptors. In the open-field test, β-PEA produced dose-dependent stereotypic behaviors, with the highest dose of 50 mg/kg significantly increasing circling behavior compared with saline-treated controls. Temporal analysis revealed that this increase was most pronounced approximately 10 minutes after administration, indicating a rapid onset of psychomotor stimulation.
Similarly, β-PEA significantly increased head-twitching responses, another stereotypic behavior associated with enhanced monoaminergic signaling, with the greatest responses occurring during the first 15 minutes following administration. Interestingly, despite these marked stereotypic behaviors, β-PEA did not significantly alter overall locomotor activity, suggesting that the compound selectively induced repetitive psychomotor behaviors rather than generalized hyperactivity. These findings indicate that acute β-PEA administration produces distinct behavioral changes that resemble those observed with psychostimulant compounds while demonstrating a unique behavioral profile characterized by stereotypy rather than increased locomotion [1] .
Behavioral measures of reward further demonstrated that β-PEA possesses rewarding properties. During the CPP experiment, no differences in chamber preference were observed among treatment groups before conditioning, confirming that the animals had no inherent preference for either compartment. Following repeated conditioning sessions, however, mice receiving 50 mg/kg β-PEA spent significantly more time in the drug-paired compartment than saline-treated controls, resulting in a significant increase in CPP scores. These findings demonstrate that β-PEA successfully established positive contextual associations, indicating that the compound possesses rewarding effects capable of reinforcing environmental cues associated with drug exposure. Complementing these findings, ultrasonic vocalization recordings showed that acute β-PEA administration significantly increased the number of 50-kHz ultrasonic vocalizations, particularly during the first 10 minutes after injection. Because 50-kHz vocalizations are widely recognized as indicators of positive emotional and motivational states in rodents, these results suggest that β-PEA induces an acute positive affective state in addition to its rewarding behavioral effects [1].
The intravenous self-administration experiments provided strong evidence that β-PEA functions as a reinforcing stimulus. Under both FR1 and FR3 schedules of reinforcement, rats receiving the highest dose of β-PEA of 1.0 mg/kg per infusion exhibited significantly greater numbers of drug infusions and active lever presses than saline-treated animals, while inactive lever responding remained unchanged. This selective increase in active responding demonstrated that the animals were intentionally working to obtain β-PEA rather than displaying nonspecific increases in activity. Temporal analyses further showed that animals consistently self-administered β-PEA throughout the testing sessions, confirming stable reinforcing behavior. Reinforcing efficacy was examined more rigorously using a progressive-ratio schedule, where the response requirement increased after each infusion. Under these demanding conditions, rats self-administering the highest β-PEA dose achieved significantly higher breakpoints, earned more total infusions, and generated substantially more active lever responses than control animals. The increased breakpoint indicated that the animals were willing to perform progressively greater amounts of work to obtain β-PEA, demonstrating robust reinforcing properties comparable to those observed with other psychostimulant drugs in preclinical models.
Biochemical analyses revealed that these behavioral effects were accompanied by significant alterations in dopaminergic signaling within the dorsal striatum. Acute β-PEA administration significantly increased dopamine concentrations in this brain region compared with saline controls. Western blot analysis further demonstrated elevated expression of tyrosine hydroxylase, the rate-limiting enzyme responsible for dopamine synthesis, and increased phosphorylation of the dopamine transporter (p-DAT), suggesting enhanced dopamine production and altered dopamine transporter activity. In contrast, total dopamine transporter (DAT) and vesicular monoamine transporter-2 (VMAT-2) expression remained unchanged, indicating that β-PEA primarily influenced dopamine neurotransmission through functional modulation rather than changes in overall protein abundance. These neurochemical findings strongly support the conclusion that β-PEA enhances dopaminergic neurotransmission within the dorsal striatum, providing a mechanistic explanation for its rewarding and reinforcing behavioral effects [1].
Pharmacological inhibition of dopamine D1 receptors further established the importance of dopaminergic signaling in mediating β-PEA’s behavioral actions. Pretreatment with the selective D1 receptor antagonist SCH23390 significantly reduced β-PEA-induced circling behavior without affecting overall locomotion or head-twitching responses, suggesting that D1 receptor activation specifically contributes to certain stereotypic behaviors. More importantly, SCH23390 markedly decreased β-PEA self-administration by significantly reducing both active lever responses and the number of drug infusions throughout the testing session. These findings demonstrate that dopamine D1 receptor activation is critical for the reinforcing properties of β-PEA and substantially contributes to its abuse-related behavioral profile. Collectively, the results indicate that β-PEA possesses rewarding, reinforcing, psychomotor, and positive affective properties that are mediated through enhanced dopaminergic neurotransmission and dopamine D1 receptor activation within the dorsal striatum, highlighting mechanisms that may underlie both its psychoactive effects and its potential for abuse [1].
2) The study by researchers Kundu et al established a clear structure–activity relationship among 29 β-PEA derivatives by demonstrating that relatively small structural modifications substantially altered their ability to inhibit dopamine reuptake through the human DAT. Initial screening identified several compounds with measurable inhibitory activity, after which the most active molecules underwent concentration-response testing to determine their IC₅₀. The results showed considerable variability in potency across the different chemical classes, indicating that both aromatic substitutions and modifications to the amine-containing side chain strongly influenced DAT inhibition. Among the arylalkylamine derivatives, compounds containing unsubstituted phenyl or thiophenyl groups generally exhibited stronger dopamine reuptake inhibition than compounds containing methoxy-substituted aromatic rings. In particular, methoxy substitutions markedly reduced or completely eliminated inhibitory activity, demonstrating that the electronic and steric properties of the aromatic ring are major determinants of transporter binding. Likewise, alterations in the alkylamine substituent influenced activity, with certain secondary amine substitutions producing greater inhibition than others depending on the accompanying aromatic structure. These findings demonstrated that optimal dopamine transporter inhibition requires a specific combination of aromatic and amine substitutions rather than modification of a single structural feature [2].
The second group of compounds, consisting of 2-(alkyl amino)-1-arylalkan-1-one derivatives, revealed additional structural requirements for effective DAT inhibition. The investigators found that compounds containing smaller heterocyclic rings, particularly pyrrolidine derivatives, consistently exhibited greater potency than molecules containing larger ring systems such as azepane or piperazine. Furthermore, extending the carbon chain attached to the amino group progressively increased inhibitory activity, with hexyl-substituted derivatives demonstrating substantially greater potency than shorter ethyl- or propyl-containing analogs. Replacing a phenyl ring with a naphthyl group also enhanced inhibitory effects in selected compounds. Among all molecules examined, compound 28, an alkyl 2-phenyl-2-(piperidin-2-yl)acetate derivative, exhibited the strongest dopamine reuptake inhibition with an IC₅₀ of approximately 68 nM, making it the most potent DAT inhibitor identified in the study. Compound 9 also demonstrated high potency among the arylalkylamine derivatives, whereas many methoxy-substituted analogs displayed little or no measurable activity. Collectively, these observations enabled the investigators to establish detailed structure–activity relationships identifying the molecular features that favor dopamine transporter inhibition.
Computational docking simulations further explained the experimental findings by demonstrating favorable molecular interactions between the most potent compounds and the human dopamine transporter. All four docking algorithms consistently predicted that the (S)-enantiomer of compound 9 exhibited greater binding stability than its corresponding (R)-form, while the (R,S)-stereoisomer of compound 28 produced the most favorable docking scores among its possible stereoisomers. The predicted binding poses showed that both compounds occupied the dopamine-binding pocket of DAT in a manner similar to endogenous dopamine. Hydrogen bonding with the conserved Asp79 residue, together with multiple hydrophobic interactions involving residues located on transmembrane helices 1, 3, 6, and 8, appeared to stabilize ligand binding. Compound 28 formed additional hydrophobic contacts with Phe320, providing a structural explanation for its superior inhibitory potency compared with other derivatives. These computational results closely paralleled the biochemical assays and demonstrated that stereochemistry and specific protein-ligand interactions are major contributors to DAT affinity [2].
Functional experiments examining dopamine D2 receptor signaling demonstrated that dopamine transporter activity significantly influenced receptor regulation. Dopamine stimulation induced approximately 40% internalization of D2 receptors in cells expressing the receptor alone. However, co-expression of the dopamine transporter markedly reduced receptor endocytosis, consistent with enhanced dopamine clearance from the extracellular environment and reduced receptor activation. Pretreatment with the potent DAT inhibitors, particularly compound 28 and compound 29, significantly reversed this transporter-mediated suppression of receptor internalization by restoring extracellular dopamine availability. These findings indicate that inhibition of dopamine reuptake not only elevates synaptic dopamine concentrations but also alters downstream dopamine receptor signaling by facilitating D2 receptor activation and endocytosis. Interestingly, although compound 28 exhibited greater potency as a DAT inhibitor than compound 29, it produced a somewhat weaker restoration of D2 receptor endocytosis, suggesting that mechanisms beyond simple transporter inhibition may contribute to receptor regulation [2].

Figure 1: Disinhibitory effects of compounds 28 and 29 DAT-mediated inhibition of dopamine receptor endocytosis.
Overall, the study successfully identified multiple structural determinants governing dopamine transporter inhibition by β-phenethylamine derivatives and demonstrated that these compounds exert meaningful functional effects on dopaminergic signaling. The combined biochemical, computational, and cellular findings showed that optimal DAT inhibition depends on precise aromatic substitutions, favorable alkylamine configurations, appropriate stereochemistry, and stable molecular interactions within the transporter binding pocket. In addition to defining the structural features associated with high DAT affinity, the study demonstrated that potent dopamine reuptake inhibitors can modify dopamine D2 receptor signaling by increasing extracellular dopamine concentrations. These findings provide valuable insight into the design of selective dopamine transporter inhibitors and suggest that appropriately optimized β-phenethylamine derivatives may serve as useful lead compounds for the development of future therapeutics targeting neuropsychiatric disorders involving dopaminergic dysfunction, while also highlighting their potential psychoactive properties and the need for careful pharmacological evaluation [2].

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Citations

[1] Ryu IS, Kim OH, Kim JS, et al. Effects of β-Phenylethylamine on Psychomotor, Rewarding, and Reinforcing Behaviors and Affective State: The Role of Dopamine D1 Receptors. Int J Mol Sci. 2021;22(17):9485. Published 2021 Aug 31. doi:10.3390/ijms22179485

[2] Kundu D, Zhu A, Kim E, et al. Potential Functional Role of Phenethylamine Derivatives in Inhibiting Dopamine Reuptake: Structure-Activity Relationship. Biomol Ther (Seoul). 2023;31(1):108-115. doi:10.4062/biomolther.2022.047